Evidence map›Paper›PMID 32557179›Full record

ArticleDrug safety2020

Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project.

Bissan Audeh, Florelle Bellet, Marie-Noëlle Beyens, Agnès Lillo-Le Louët, Cédric Bousquet

Abstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in Drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Pharmacovigilance in the digital age: gaining insight from social media data.Experimental biology and medicine (Maywood, N.J.) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. [Utilizing social media data in post-market safety surveillance].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bissan AudehLaboratoire d'informatique médicale et d'ingénierie des Connaissances en e-santé, LIMICS, Sorbonne Université, Inserm, Université Paris 13, 75006, Paris, France. bissan.audeh@gmail.com.ORCID 0000-0001-8550-8724
Florelle BelletCentre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France.
Marie-Noëlle BeyensCentre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France.
Agnès Lillo-Le LouëtCentre Régional de Pharmacovigilance HEGP, AP-HP, Paris, France.
Cédric BousquetLaboratoire d'informatique médicale et d'ingénierie des Connaissances en e-santé, LIMICS, Sorbonne Université, Inserm, Université Paris 13, 75006, Paris, France.

Funding

Agence Nationale de Sécurité du Médicament et des Produits de Santé 2016S076Agence Nationale de Sécurité du Médicament et des Produits de Santé AAP-2013-052
6 · The paper itself

Abstract

The large-scale use of social media by the population has gained the attention of stakeholders and researchers in various fields. In the domain of pharmacovigilance, this new resource was initially considered as an opportunity to overcome underreporting and monitor the safety of drugs in real time in close connection with patients. Research is still required to overcome technical challenges related to data extraction, annotation, and filtering, and there is not yet a clear consensus concerning the systematic exploration and use of social media in pharmacovigilance. Although the literature has mainly considered signal detection, the potential value of social media to support other pharmacovigilance activities should also be explored. The objective of this paper is to present the main findings and subsequent recommendations from the French research project Vigi4Med, which evaluated the use of social media, mainly web forums, for pharmacovigilance activities. This project included an analysis of the existing literature, which contributed to the recommendations presented herein. The recommendations are categorized into three categories: ethical (related to privacy, confidentiality, and follow-up), qualitative (related to the quality of the information), and quantitative (related to statistical analysis). We argue that the progress in information technology and the societal need to consider patients' experiences should motivate future research on social media surveillance for the reinforcement of classical pharmacovigilance.

Indexed as

Adverse Drug Reaction Reporting SystemsPharmacovigilanceSocial MediaFranceHumansResearch Design

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.